Kyverna Therapeutics Share Price Today

Halper Sadeh probes Kyverna Therapeutics over fiduciary breaches

Halper Sadeh LLC investigates Kyverna Therapeutics for fiduciary duty breaches. Investigation announced November 12, 2026, targeting long-term shareholders. Adds to existing Kahn Swick & Foti probe into IPO disclosure allegations. Shareholders may seek governance reforms or financial incentives.

Kyverna Therapeutics Q3 Results: Loss per share narrows 20% YoY

Kyverna Therapeutics reported a Q3 loss of $0.68 per share. The result beat the analyst consensus estimate of $0.69 by 1.45%. Losses narrowed by 20% compared to $0.85 per share in the same period last year.

Kyverna publishes miv-cel SPS trial data in JAMA Neurology

Published KYSA-8 registrational trial data in JAMA Neurology on November 9, 2026. 67% of patients requiring walking aids at baseline regained independent mobility at 16 weeks. All trial participants discontinued chronic immunotherapies following single-dose treatment. Safety profile showed no high-grade CRS, ICANS, or IEC-HS cases. Miv-cel holds three FDA RMAT designations for neurologic autoimmune diseases.

Kyverna miv-cel shows durable one-year benefit in stiff person syndrome

Median improvement in timed 25-Foot Walk reached 49% at one year, up from 46% at week 16. 92% of patients remained free of chronic immunotherapies throughout the one-year follow-up. No cases of high-grade CRS, ICANS, or IEC-HS were reported in the safety profile. Data supports potential for miv-cel to be the first approved CAR T-cell therapy for autoimmune diseases.

Kyverna reports durable miv-cel data in SPS and gMG trials

Kyverna reported sustained clinical benefit in SPS patients at one year, with 95% maintaining initial improvements. In gMG trials, 86% of patients remained off immunosuppressants at last follow-up, with durable effects up to 1.5 years. No high-grade CRS, ICANS, or IEC-HS cases were observed, supporting a favorable safety profile. Rolling BLA submission for SPS is on track for completion in Q4 2026, with Phase 3 enrollment ending mid-2027.

Kyverna Therapeutics to present at Wells Fargo, Morgan Stanley, and H.C. Wainwright conferences

Kyverna Therapeutics management to present at three major healthcare conferences in September 2026. Events include Wells Fargo (Sept 9), Morgan Stanley (Sept 14), and H.C. Wainwright (Sept 15). Live webcasts and 90-day archived replays available via company investor relations website. Company focuses on CD19-targeting CAR T-cell therapy for neurologic autoimmune diseases.